GlobeNewswire

Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates

Share

Five ongoing late-stage trials on track for data readouts in 2019

WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2018.

“We are proceeding with the enrollment of patients in five late-stage clinical efficacy trials with three innovative product candidates that address significant unmet needs in large CNS markets,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.  “Our attention is focused on the careful execution of these trials, including patient selection, clinical site monitoring and close interaction with investigators.

“During the past quarter, The Journal of Clinical Psychiatry published online Phase 2b trial results demonstrating cognitive improvements in patients with schizophrenia treated with roluperidone (MIN-101),” said Dr. Luthringer.  “Cognitive improvements were observed to correlate with previously reported improvements in negative symptoms, an important finding given that cognitive impairment, like negative symptoms, is a primary driver of functional disability in schizophrenia and a significant unmet medical need for patients with this disease.”

The ongoing trials with the Company’s clinical-stage product candidates include the following:

  • Roluperidone: Phase 3 trial to treat negative symptoms in patients diagnosed with schizophrenia (monotherapy); top line results from the 12-week double blind phase of this trial are expected in the first half of 2019.
  • MIN-117: Phase 2b trial to treat patients with major depressive disorder who also have symptoms of anxiety (monotherapy); top-line results are expected in the first half of 2019.
  • Seltorexant (MIN-202): two Phase 2b trials to treat patients with major depressive disorder (adjunctive therapy); results expected in 2019.
  • Seltorexant: one Phase 2b trial to treat patients with insomnia disorder (monotherapy); results expected in 2019.

Second Quarter 2018 Financial Results

  • Cash Position: Cash, cash equivalents, restricted cash and marketable securities as of June 30, 2018 were approximately $108.6 million, compared to $133.3 million as of December 31, 2017.    
     
  • R&D Expenses: Research and development (R&D) expenses were $9.1 million in the second quarter of 2018, compared to $7.1 million in the second quarter of 2017, an increase of $2.0 million.  The increase in R&D expenses primarily reflects higher development expenses for the Phase 3 clinical trial of roluperidone and the Phase 2b clinical trial of MIN-117. These amounts were partially offset by lower development expenses for the seltorexant program due to the Amendment to our Co-Development and License Agreement with Janssen. We expect R&D expenses to increase during 2018 as we increase patient enrollment and related support activities for the roluperidone and MIN-117 clinical trials.

    For the six months ended June 30, 2018, R&D expenses were $17.5 million, compared to $14.8 million for the six months ended June 30, 2017, an increase of $2.7 million.  The increase in R&D expenses primarily reflects higher development expenses for the Phase 3 clinical trial of roluperidone and the Phase 2b clinical trial of MIN-117. These amounts were partially offset by lower development expenses for the seltorexant program due to the Amendment to our Co-Development and License Agreement with Janssen. We expect R&D expenses to increase during 2018 as we increase patient enrollment and related support activities for the roluperidone and MIN-117 clinical trials.     
  • G&A Expenses: General and administrative (G&A) expenses were $3.9 million in the second quarter of 2018, compared to $2.6 million in the second quarter of 2017, an increase of approximately $1.3 million.  This increase in G&A expenses was primarily due to an increase in non-cash stock-based compensation expenses and salary costs from increased staffing to support our pre-commercial activities.  We expect G&A expenses to increase during 2018 as we begin to invest in the infrastructure necessary to support the Company’s growth.

    For the six months ended June 30, 2018, G&A expenses were $8.2 million, compared to $5.5 million for the same period in 2017, an increase of approximately $2.7 million. This increase in G&A expenses was primarily due to an increase in non-cash stock-based compensation expenses and salary costs from increased staffing to support our pre-commercial activities.  We expect G&A expenses to increase during 2018 as we begin to invest in the infrastructure necessary to support the Company’s growth.      
  • Net Loss: Net loss was $12.5 million for the second quarter of 2018, or a loss per share of $0.32 (basic and diluted), as compared to a net loss of $9.8 million, or a loss per share of $0.27 (basic and diluted) for the second quarter of 2017.  Net loss was $24.9 million for the first six months of 2018, or a loss per share of $0.64 (basic and diluted), as compared to a net loss of $20.4 million, or a loss per share of $0.57 (basic and diluted) for the first six months of 2017.

Conference Call Information:

Minerva Neurosciences will host a conference call and live audio webcast today at 8:30 a.m. Eastern Time to discuss the quarter and recent business activities.  To participate, please dial (877) 312-5845 (domestic) or (765) 507-2618 (international) and refer to conference ID 1686118.

The live webcast can be accessed under “Events and Presentations” in the Investors and Media section of Minerva’s website at ir.minervaneurosciences.com.  The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases.  Minerva’s proprietary compounds include: roluperidone (MIN-101), in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit www.minervaneurosciences.com

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and scope of current clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the timing and scope of future clinical trials and results of clinical trials with these compounds; the clinical and therapeutic potential of these compounds; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management’s ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, filed with the Securities and Exchange Commission on August 2, 2018.  Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

 
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(Unaudited)
  June 30, December 31,
  2018     2017  
  (in thousands)
ASSETS
Current Assets:    
Cash and cash equivalents $ 68,689   $ 26,052  
Marketable securities   39,799     102,109  
Restricted cash   100     80  
Prepaid expenses and other current assets   3,229     1,299  
Total current assets   111,817     129,540  
Marketable securities - noncurrent   -     5,023  
Equipment, net   42     51  
Other noncurrent assets   15     15  
In-process research and development   34,200     34,200  
Goodwill   14,869     14,869  
Total Assets $ 160,943   $ 183,698  
     
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:    
Notes payable $ 1,397   $ 3,962  
Accounts payable   1,310     1,436  
Accrued expenses and other current liabilities   2,311     1,439  
Total current liabilities   5,018     6,837  
Long-Term Liabilities:    
Deferred taxes   4,057     4,057  
Deferred revenue   41,176     41,176  
Other noncurrent liabilities   31     30  
Total liabilities   50,282     52,100  
Stockholders' Equity:    
Common stock   4     4  
Additional paid-in capital   299,986     295,975  
Accumulated deficit   (189,329 )   (164,381 )
Total stockholders' equity   110,661     131,598  
Total Liabilities and Stockholders' Equity $ 160,943   $ 183,698  
     
       
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS      
(Unaudited)            
    Three Months Ended June 30,   Six Months Ended June 30,
    (in thousands, except per share amounts)   (in thousands, except per share amounts)
      2018     2017       2018     2017  
             
Revenues   $   -    $   -      $   -    $   -   
Operating expenses:            
Research and development       9,062       7,144         17,512       14,758  
General and administrative       3,873       2,601         8,167       5,472  
Total operating expenses       12,935       9,745         25,679       20,230  
             
Foreign exchange losses       29       (20 )       11       (37 )
Investment income       412       156         826       214  
Interest expense       (36 )     (170 )       (106 )     (372 )
Net income (loss)   $   (12,530 ) $   (9,779 )   $   (24,948 ) $   (20,425 )
Loss per share:            
Basic and diluted   $   (0.32 ) $   (0.27 )   $   (0.64 ) $   (0.57 )
Weighted average shares:            
Basic and diluted       38,749       36,720         38,749       36,048  
             

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Hexagon Composites ASA: Mandatory Notification of Trade5.6.2020 17:11:41 CESTPress release

Dan Krick, SVP Organizational Development has sold 24,896 shares in Hexagon Composites ASA at a price of NOK 36,42 per share. The sale is primarily to finance tax obligations from his exercise of options earlier in the year. After the transaction Dan Krick holds zero shares in Hexagon Composites ASA. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. For more information: David Bandele, CFO, Hexagon Composites ASA Telephone: +47 920 91 483 | david.bandele@hexagongroup.com About Hexagon Composites Hexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation and conversion to clean energy in a wide range of mobility, industrial and consumer applications.

CONDITIONS FOR RIKSBANK BID PROCEDURES SEK GOVERNMENT BONDS5.6.2020 15:05:00 CESTPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2020-06-12 Maturity dateLoanISIN codeCouponVolume, SEK million2026-11-121059 SE00071259271.00 %1,000 +/- 2502031-05-12 1062 SE00139353190.125 %1,000 +/- 250 Settlement date 2020-06-16 Bids have to be entered by 10.00 on JUN 12, 2020 Highest permitted bid volume: 1 000 SEK million in issue SGB 1059 and 1 000 SEK million in issue SGB 1062 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST) ON JUN 12, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved athttp://www.riksbank.se

Correction: Correction: Correction: AB Klaipedos nafta financial information reporting dates in 20205.6.2020 15:05:00 CESTPress release

Correction: AB Klaipedos nafta social responsibility report for the year 2019 will be released on 9 June 2020. AB Klaipedos nafta (further – KN) informs that it plans to release financial information in 2020 according to the following schedule: DateReporting informationWithin first 5 working days of every month of 2020KN preliminary revenues* for the previous month31 January 2020Interim financial information for the year 20196 April 2020Audited financial statements for the year 201929 April 2020Interim financial information for the 1st quarter of 20209 June 2020Social responsibility report for the year 201931 July 2020Interim financial information for the 6 month of 202030 October 2020Interim financial information for the 3 quarters of 2020 On 28 April 2020, the Company plans to convene an Ordinary General Meeting of Shareholders. * It should be noted that from 2020 the company will be adjusting course of releasing monthly financial information. As range of the services provided to the

Medtronic Resolute Onyx™ DES Receives First and Only One-Month DAPT Indication for High Bleeding Risk Patients in Europe5.6.2020 15:00:10 CESTPress release

DUBLIN, June 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for a one-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx™ Drug-Eluting Stent (DES). For HBR patients, whose bleeding risk may be increased by taking longer DAPT regimens (a combination of aspirin and anti-clotting medication), this new, first-of-its-kind indication allows physicians to recommend a shorter, one-month regimen of DAPT, following a percutaneous coronary intervention (PCI) with Resolute Onyx. The approval is the first of its kind globally. Resolute Onyx DES is available for use in the United States, as well as in Europe and other countries that recognize the CE Mark. Resolute Onyx DES is not currently indicated for HBR patients with one-month DAPT in the United States. Data have been submitted to the FDA with the intent of obtainin

Conditions for Riksbank Bid Procedures Sek Covered Bonds5.6.2020 15:00:00 CESTPress release

Conditions for Riksbank Bid Procedures Sek Bonds Sveriges Riksbank Bid procedure details Covered Bonds, 2020-06-11 Maturity dateLoanISIN codeCouponVolume, SEK million2022-04-08 5531 SE00069912461.00 %1,000 +/- 5002021-12-15 574 SE00081034771.50 %1,000 +/- 500 2021-12-151585SE00089925151.50 %1,000 +/- 5002022-06-15191SE00075256541.00 %1,000 +/- 5002021-12-152112SE00104947161.00 %400 +/- 2502021-09-15514SE00065433281.75 %400 +/- 2502022-06-15143SE00085866551.25 %400 +/- 250 Settlement date 2020-06-15 Bids have to be entered by 10.00 on JUN 11 2020 Highest permitted bid volume: 1,000 SEK million in issue 5531 1,000 SEK million in issue 574 1,000 SEK million in issue 1585 1,000 SEK million in issue 191 400 SEK million in issue 2112 400 SEK million in issue 514 400 SEK million in issue 143 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON JUN 11, 2020. For more information,

AB Klaipėdos nafta preliminary revenue for the May 20205.6.2020 15:00:00 CESTPress release

AB Klaipėdos nafta, (further the Company) reviewed operating segments since the beginning of the second quarter of 2020 and presents revenue disclosures accordingly. The following operating segments of the Company are: Oil terminals activity, that includes Klaipėda oil terminal and Subačius oil terminal,Regulated LNG activity in Klaipėda andCommercial LNG activity, that includes small-scale LNG reloading station in Klaipėda and Business development projects. The preliminary sales revenue of the Company’s oil terminals for the May 2020 comprised EUR 3.1 million and is higher by EUR 0.8 million or by 34.8 per cent compared to May of 2019. The preliminary sales revenue is higher due to increase of sales of oil products storage, if compared to the same period of 2019. The preliminary sales revenue of the Company’s oil terminals for the first five months of 2020 comprised EUR 13.7 million, i.e. higher by 6.2 per cent, compared to the same period of 2019. The preliminary sales revenue of the